286 related articles for article (PubMed ID: 24851906)
1. Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.
Stavrou S; Crawford D; Blouch K; Browne EP; Kohli RM; Ross SR
PLoS Pathog; 2014 May; 10(5):e1004145. PubMed ID: 24851906
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
5. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
6. Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.
Wang Y; Schmitt K; Guo K; Santiago ML; Stephens EB
J Gen Virol; 2016 Jan; 97(1):1-17. PubMed ID: 26489798
[TBL] [Abstract][Full Text] [Related]
7. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.
Goila-Gaur R; Khan MA; Miyagi E; Kao S; Strebel K
Retrovirology; 2007 Aug; 4():61. PubMed ID: 17727729
[TBL] [Abstract][Full Text] [Related]
8. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
9. Repair of APOBEC3G-Mutated Retroviral DNA
Salas-Briceno K; Ross SR
J Virol; 2021 Oct; 95(22):e0124421. PubMed ID: 34468176
[TBL] [Abstract][Full Text] [Related]
10. The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.
Cadena C; Stavrou S; Manzoni T; Iyer SS; Bibollet-Ruche F; Zhang W; Hahn BH; Browne EP; Ross SR
Retrovirology; 2016 Jun; 13(1):45. PubMed ID: 27363431
[TBL] [Abstract][Full Text] [Related]
11. Deaminase-Dead Mouse APOBEC3 Is an
Stavrou S; Zhao W; Blouch K; Ross SR
J Virol; 2018 Jun; 92(11):. PubMed ID: 29593034
[TBL] [Abstract][Full Text] [Related]
12. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
13. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
15. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
[TBL] [Abstract][Full Text] [Related]
17. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
Dang Y; Wang X; Zhou T; York IA; Zheng YH
J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
20. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
